Irinotecan liposome II combination therapy regimen

DRUG2 trials

Sponsors

Peking Union Medical College Hospital, First Affiliated Hospital of Chongqing Medical University

Conditions

Non-Muscle Invasive Bladder Urothelial CarcinomaPancreatic Cancer

Phase 1

Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment

RecruitingNCT06766266

First Affiliated Hospital of Chongqing Medical UniversityNon-Muscle Invasive Bladder Urothelial Carcinoma

Start: 2025-01-10End: 2025-12-24Target: 18Updated: 2025-03-26

Unknown Phase

Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients

RecruitingNCT06375473

Peking Union Medical College HospitalPancreatic Cancer

Start: 2024-04-19End: 2027-04-19Target: 3000Updated: 2026-01-06

Related Papers

Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair

Signal Transduction and Targeted Therapy2025-07-1011 citations